Dr. Pavel KHODAKOVSKIY
Pavel Khodakovskiy was born in Ukraine in 1979. He got his Master of Science in Chemistry at the department of inorganic chemistry of Taras Shevchenko University of Kyiv under the supervision of prof. Vitaly V. Pavlishchuk in 2001. He then joined rapidly growing company Enamine Ltd. where he gained tremendous experience in organic synthesis. Pavel realized his PhD work at Taras Shevchenko University of Kyiv under the supervision of prof. Andrey A. Tolmachev in 2010. His thesis “Synthesis and reactions of 2-trifluoroacetyl-1,3-azoles” is focuses on the synthesis highly electrophilic CF3-containing heterocyclic ketones and their reactions with various nucleophileseactions.
Dr. Arkadiy BAZHIN
Arkadiy was born in Perm, Russia and obtained his M.S. degree (2010) from Perm State Pharmaceutical Academy in the field of Pharmaceutical chemistry. The topic of his master thesis reasearch was “Chemical composition and anticoagulant activity of extracts from Euphrasia L. species”. After graduation with his MS degree, he started working in the laboratoryof medicinal chemistry at under supervision of Professor Olga Krasnykh on two major projects. The first one included development of new phosphodiesterase-5 inhibitors and the second project was on the topic of elucidating molecular targets for compounds that show anti-inflammatory activity in animals.
Dr. Kaycie DEYLE
Kaycie completed her B.S. degree in biochemistry at the Indiana University of Pennsylvania, USA. She then joined the California Institute of Technology (Caltech) where she earned a Ph.D. in chemistry in the lab of Prof. James Heath. Her graduate work focused on the use of one-bead, one-compound chemically synthesized libraries for the development of peptide binding agents that could detect single amino acid point mutations in cancer proteins. Kaycie then joined the lab of Prof. Christian Heinis at EPFL for postdoctoral work in phage-display screening for peptide drug candidates.
Dr. Christian LAUBER
Christian is a Scientist in the Institute of Chemical Sciences and Engineering at the École Polytechnique Fédéral de Lausanne helping to develop non-invasive methods to monitor microbial community processes in vivo. He obtained his PhD in Biology from the University of New Mexico in the lab of Robert Sinsabaugh and completed a postdoc with Noah Fierer at the University of Colorado (CU), describing how soil microbial community function and diversity vary across ecosystems and respond to disturbances. He went on to work for Rob Knight at CU to focus on the human microbiome and took this experience to the Nestlé Institute of Health Sciences in Lausanne, Switzerland where his research centered on the microbe-diet-host nexus. Dr. Lauber has a deep interest in microbial interactions and uses a multi-disciplinary approach to identify relationships with the environment and other organisms that support the health and stability of ecosystems.
Tamara was born in Ljubljana, Slovenia and received her MS degree in 2015 from University of Ljubljana in the field of Biochemistry. She did her Bachelor and Master thesis at the Institute of Jozef Stefan, Ljubljana in the department of Biochemistry and Molecular Biology. Her master thesis focused on investigation of protein interaction between Procathepsin B and light chain of Annexin II (p11). During the second master semester she did an exchange at National University of Maynooth, Ireland (NUIM).
Her main research is focused on the development of bioluminescent probes for monitoring metabolic fluxes real time in living system using biocompatible chemical reactions
Pier Luca D’ALESSANDRO
Pier Luca studied medicinal chemistry at the University of Genoa (IT). He received his MSc in 2003 and then joined GlaxoSmithKline in Harlow (UK) as research scientist. At GSK, he worked first in the high-throughput chemistry department using solid phase synthesis (Irori Kans technology) and solution phase parallel synthesis. After this experience, he moved to the Psychiatry Centre of Excellence for Drug Discovery of GSK working on hit to candidate drug discovery projects (e.g. mGLUR2 positive modulator, mGLUR5 antagonist). In 2008, he moved to Novartis in Basel (CH) where he joined the Musculoskeletal Disease Unit as a medicinal chemist before moving to his current position in the New Modalities Group of Global Discovery Chemistry. In 2014, while working for Novartis, he joined the group of Prof. Elena Goun at EPFL as PhD student. His PhD project aims at the validation of bioorthogonal chemical probes in cell disease model using imaging technologies.